Actuate Therapeutics Features Post-Hoc Efficacy And Biomarker Analyses From Randomized Phase 2 Study, Along With Clinical Data From Phase 2 Study Of Elraglusib In Combination With FFX And TGF-Β Inhibitor Losartan In mPDAC Patients, At 2026 ASCO

- Patients with KRAS wild-type (WT) genomics achieved significant improvement in median overall survival (mOS) when treated with elraglusib plus gemcitabine/Abraxane (GnP) versus GnP alone

- Patients with P53WT genomics receiving elraglusib plus GnP showed a near doubling of mOS versus GnP alone

- Patients receiving elraglusib plus FOLFIRINOX demonstrated deep and sustained clinical responses and increased mOS versus FOLFIRINOX alone or in combination with losartan

- Elraglusib treatment was well tolerated when used in combination with either GnP or FOLFIRINOX

CHICAGO and FORT WORTH, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU), a clinical-stage biopharmaceutical company focused on developing novel therapies for difficult-to-treat cancers, today announced that two presentations were given at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentations featured post-hoc efficacy and biomarker analyses from the randomized Phase 2 study (NCT03678883), along with clinical data from a Phase 2 study conducted at Mass General Brigham Cancer Institute of elraglusib in combination with FOLFIRINOX (FFX) and the TGF-β inhibitor losartan in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).